var data={"title":"Calcitonin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Calcitonin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5784?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=calcitonin-drug-information\" class=\"drug drug_general\">see &quot;Calcitonin: Drug information&quot;</a> and <a href=\"topic.htm?path=calcitonin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Calcitonin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144121\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fortical [DSC];</li>\n      <li>Miacalcin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144122\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Calcimar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057074\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Hypercalcemia</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057068\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=calcitonin-drug-information\" class=\"drug drug_general\">see &quot;Calcitonin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Osteogenesis imperfecta:</b> Infants &gt;6 months, Children, and Adolescents: IM, SubQ: 2 units/kg/dose 3 times/week (Castells, 1979)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Paget's disease:</b> Miacalcin: IM, SubQ: Initial: 100 units/day; maintenance dose: 50 units/day or 50-100 units every 1-2 days; may be preferable to maintain doses of 100 units daily for serious deformity or neurologic involvement</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypercalcemia:</b> Miacalcin: Initial: IM, SubQ: 4 units/kg every 12 hours for 1-2 days; may increase up to 8 units/kg every 12 hours; if the response remains unsatisfactory after 2 additional days, a further increase up to a maximum of 8 units/kg every 6 hours may be considered</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postmenopausal osteoporosis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miacalcin: IM, SubQ: 100 units every other day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fortical, Miacalcin: Intranasal: 200 units (1 spray) into <b>one</b> nostril daily </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144099\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miacalcin: 200 units/mL (2 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortical: 200 units/actuation (3.7 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miacalcin: 200 units/actuation (3.7 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 units/actuation (3.7 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144084\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057078\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intranasal: Before first use, allow bottle to reach room temperature, then prime pump by releasing at least 5 sprays until full spray is produced. To administer, place nozzle into nostril with head in upright position. Spray into <b>one</b> nostril daily; alternate nostrils to reduce irritation. Do not prime pump before each daily use. Discard after 30 doses. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: May be administered SubQ or IM; do not exceed 2 mL volume per injection site; SubQ is preferred for outpatient self administration unless the injection volume is &gt;2 mL; IM is preferred  if the injection volume is &gt;2 mL (use multiple injection sites if dose volume is &gt;2 mL). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144116\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from freezing. The following stability information has also been reported: May be stored at room temperature for up to 14 days (Cohen, 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nasal: Store unopened bottle under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortical: After opening, store for up to 30 days at 20&#730;C to 25&#730;C (68&#730;F to 77&#730;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store in upright position.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miacalcin: After opening, store for up to 35 days at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store in upright position.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057077\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: Treatment of Paget's disease of bone; adjunctive therapy for hypercalcemia; postmenopausal osteoporosis (FDA approved in adults); has also been used for osteogenesis imperfecta </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intranasal: Postmenopausal osteoporosis in women &gt;5 years postmenopause with low bone mass (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144173\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Calcitonin may be confused with calcitriol </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortical may be confused with Foradil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miacalcin may be confused with Micatin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Calcitonin nasal spray is administered as a single spray into <b>one</b> nostril daily, using alternate nostrils each day.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144171\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Depression, dizziness, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythematous rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Lymphadenopathy, malignant neoplasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, myalgia, osteoarthritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Abnormal lacrimation, conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, flu-like symptoms, rhinitis (including ulcerative), sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening; all routes: Alopecia, altered sense of smell, anorexia, antibody development (drug efficacy can be affected), edema, excoriation (nasal mucosa), hearing loss, hypersensitivity reaction, nocturia, polyuria, tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144106\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to calcitonin salmon or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144088\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Salmon-derived products: Anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat have been reported; have epinephrine immediately available for a possible hypersensitivity reaction. A skin test should be performed prior to initiating therapy of calcitonin salmon in patients with suspected sensitivity; a detailed skin testing protocol is available from the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Hypocalcemia with tetany and seizure activity has been reported. Hypocalcemia and other disorders affecting mineral metabolism (eg, vitamin D deficiency) should be corrected before initiating therapy; monitor serum calcium and symptoms of hypocalcemia during therapy. Administer in conjunction with calcium and vitamin D.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Analyses of randomized controlled trials (in osteoporosis and osteoarthritis) using the nasal spray and oral formulations have demonstrated a statistically significant increase in the risk of the development of cancer in calcitonin-treated patients (compared to placebo). The risk for malignancies is associated with long-term use of calcitonin (trials ranged from 6 months to 5 years in duration). Periodically reassess continued use of calcitonin therapy, carefully considering the risks versus benefits. Similar risk for other routes (subcutaneous, IM, IV) cannot be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary sediment abnormalities: Coarse granular casts and casts containing renal tubular epithelial cells were observed following use in young adults on bed rest during a study to examine the effect of immobilization on osteoporosis; no other renal abnormalities were reported and sediment normalized after discontinuation; consider monitoring urine sediment periodically; however, the clinical significance of this finding is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: Risk vs benefit: Definitive efficacy of calcitonin-salmon in decreasing fractures is lacking compared to other agents approved for osteoporosis treatment. Consider potential benefits of therapy against risks, including the potential risk for malignancy with long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nasal spray: Rhinitis and epistaxis have been reported; mucosal alterations may occur. Perform nasal examinations with visualization of the nasal mucosa, turbinates, septum and mucosal blood vessels prior to initiation of therapy, periodically during therapy, and at any time nasal symptoms occur. Temporarily withdraw use if ulceration of nasal mucosa occurs. Discontinue for severe ulcerations &gt;1.5 mm, those that penetrate below the mucosa, or those associated with heavy bleeding. Patients &gt;65 years of age may experience a higher incidence of nasal adverse events with calcitonin nasal spray.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Fracture reduction efficacy has not been demonstrated; use has not been shown to increase spinal bone mineral density in early postmenopausal women. Use should be reserved for patients for whom alternative treatments are not suitable (eg, patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298928\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218757\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13106&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Calcitonin may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zoledronic Acid: Calcitonin may enhance the hypocalcemic effect of Zoledronic Acid. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144095\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1861980\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Miacalcin is not indicated for use in women of reproductive potential. Adverse events have been observed in animal reproduction studies. Calcitonin does not cross the placenta.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057073\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes and calcium; alkaline phosphatase and 24-hour urine collection for hydroxyproline excretion (Paget's disease); urinalysis (urine sediment); serum calcium; periodic nasal exams (intranasal use only)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144087\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Peptide sequence similar to human calcitonin; functionally antagonizes the effects of parathyroid hormone. Directly inhibits osteoclastic bone resorption; promotes the renal excretion of calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption; increases the jejunal secretion of water, sodium, potassium, and chloride</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144105\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypercalcemia: IM, SubQ: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Paget's disease: Within a few months; may take up to 1 year for neurologic symptom improvement</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Hypercalcemia: IM, SubQ: 6 to 8 hours; following multiple doses, hypercalcemic effect diminishes within 24 to 48 hours (Nilsson 1978; Stevenson 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Intranasal: Rapidly but highly variable and lower than IM administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.15 to 0.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Metabolized in kidneys, blood and peripheral tissue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: IM: 66%; SubQ: 71%; Nasal: ~3% to 5% (relative to IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination (terminal): IM 58 minutes; SubQ 59 to 64 minutes; Nasal: ~18 to 23 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: SubQ ~23 minutes; Nasal: ~10 to 13 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as inactive metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Salmon calcitonin: 3.1 mL/kg/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144108\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcitonin (Salmon) Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 units/ACT (3.7 mL): $118.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Miacalcin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 units/mL (2 mL): $3,243.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144111\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cadens (FR);</li>\n      <li>Calci-10 (TH);</li>\n      <li>Calcinin (TW);</li>\n      <li>Calcitoran (JP);</li>\n      <li>Calco (TH);</li>\n      <li>Calco [salmon] (HU);</li>\n      <li>Calsonin (KR);</li>\n      <li>Calsynar (BR, TW);</li>\n      <li>Calsynar [salmon] (HU, LU);</li>\n      <li>Cibacalcin (AE, BH, CY, EG, GR, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Cibacalcine [human] (LU);</li>\n      <li>Citonina (AR);</li>\n      <li>Forcaltonin (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HN, HU, IE, IL, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Fortical (IL);</li>\n      <li>Karil (LU);</li>\n      <li>Karil [salmon] (LU);</li>\n      <li>Menocal (KR);</li>\n      <li>Miacalcic (AE, AU, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GR, HK, HN, ID, IE, IQ, IR, IS, JO, KR, KW, LB, LK, LY, MT, MX, MY, NO, NZ, OM, PE, PH, PL, PT, QA, RU, SA, SE, SG, SI, SK, SY, TR, TW, VN, YE);</li>\n      <li>Miacalcic [salmon] (HR, HU);</li>\n      <li>Miakaltsyk (UA);</li>\n      <li>Mycalcin (TH);</li>\n      <li>Nozocalcin (BD);</li>\n      <li>Orthonase (TH);</li>\n      <li>Oseum (MX);</li>\n      <li>Osteocal (PH);</li>\n      <li>Salmocalcin (AR);</li>\n      <li>Salmocin (TH);</li>\n      <li>Tendolon (MY);</li>\n      <li>Tonocalcin (MY);</li>\n      <li>Ucecal [salmon] (LU);</li>\n      <li>Zycalcit (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Castells S, Colbert C, Chakrabarti C, et al, &quot;Therapy of Osteogenesis Imperfecta With Synthetic Salmon Calcitonin,&quot; <i>J Pediatr</i>, 1979, 95(5 Pt 1):807-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/573785/pubmed\" target=\"_blank\" id=\"573785\">573785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al. Room-temperature storage of medications labeled for refrigeration. <i>Am J Health-Syst Pharm</i>. 2007; 64(16):1711-1715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13106 Version 104.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F144121\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F144122\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057074\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057068\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F144099\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F144084\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057078\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F144116\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057077\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F144173\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F144171\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F144106\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F144088\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298928\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218757\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F144095\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1861980\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057073\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F144087\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F144105\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F144108\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F144111\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13106|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=calcitonin-drug-information\" class=\"drug drug_general\">Calcitonin: Drug information</a></li><li><a href=\"topic.htm?path=calcitonin-patient-drug-information\" class=\"drug drug_patient\">Calcitonin: Patient drug information</a></li></ul></div></div>","javascript":null}